Severe bacterial infections in adult hospitalized patients, including severe pneumonia (e.g., hospital-acquired or ventilator-associated pneumonia) and complicated intra-abdominal infections, treated with aztreonam–avibactam in routine clinical care, particularly in the context of multidrug-resistant Gram-negative pathogens.
Conditions
Interventions
Group 1: Single-arm retrospective cohort: All adult hospitalized patients treated with aztreonam–avibactam in routine clinical care (e.g., severe pneumonia or complicated intra-abdominal infection).
Sponsors
Charité – Universitätsmedizin Berlin, Klinik für Anästhesiologie und Intensivmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult hospitalized patients (=18 years) treated with aztreonam–avibactam in routine clinical care for at least 72 hours.
Exclusion criteria
Exclusion criteria: None.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical treatment success with aztreonam–avibactam (improvement or resolution of infection-related symptoms at end of therapy or hospital discharge). | — |
Secondary
| Measure | Time frame |
|---|---|
| Microbiological clearance (negative cultures after end of therapy), safety/tolerability (adverse events, treatment discontinuation), 30-/60-day mortality, ICU and hospital length of stay. | — |
Countries
Germany
Contacts
Public ContactOliver Hölsken
Charité – Universitätsmedizin Berlin, Klinik für Anästhesiologie und Intensivmedizin
Outcome results
None listed